All In MedTech

Device Trial Radar · NCT02497950

HeartMate 3 ELEVATE™ Registry

Evaluating the HeartMate 3™ in a Post-Market Approval Setting: The HeartMate 3 Registry (ELEVATE™)

Last checked: Nov 20, 2026Latest source record: Mar 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

540

Actual

Start

Oct 13, 2015

Primary completion

Feb 2019

Study completion Feb 28, 2022

Sponsor

Lead sponsor
Abbott Medical DevicesPublic (ABT)
Sponsor type
Industry
Collaborators
Thoratec Europe Ltd; Thoratec Corporation
First posted
Jul 15, 2015

More device trials from this sponsor

Design

Study type
Observational
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate real-world experience of HeartMate 3 (HM3) in post-approval setting.

Conditions

  • Heart Failure
  • Cardiovascular Disease
  • Ventricular Dysfunction

Interventions

  • HeartMate 3Device

    Any patient that is determined to meet the HM3 commercially approved labelling indication and that is implanted with the HM3

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SurvivalTime frame: Up to 5 Years post-implant

Locations

26 sites in 11 countries. Site status is shown where the registry gives one.

  • AJH - Wien

    Vienna, Austria

  • Institute for Clinical and Experimental Medicine (IKEM)

    Prague, Czechia

  • Rigshospitalet Copenhagen

    Copenhagen, Denmark

23 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.